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Abstract
Primary human hepatocytes isolated from patient biopsies represent the most physiologically relevant cell culture model for
hepatitis C virus (HCV) infection, but these primary cells are not readily accessible, display individual variability, and are
largely refractory to genetic manipulation. Hepatocyte-like cells differentiated from pluripotent stem cells provide an
attractive alternative as they not only overcome these shortcomings but can also provide an unlimited source of noncancer
cells for both research and cell therapy. Despite its promise, the permissiveness to HCV infection of differentiated human
hepatocyte-like cells (DHHs) has not been explored. Here we report a novel infection model based on DHHs derived from
human embryonic (hESCs) and induced pluripotent stem cells (iPSCs). DHHs generated in chemically defined media under
feeder-free conditions were subjected to infection by both HCV derived in cell culture (HCVcc) and patient-derived virus
(HCVser). Pluripotent stem cells and definitive endoderm were not permissive for HCV infection whereas hepatic progenitor
cells were persistently infected and secreted infectious particles into culture medium. Permissiveness to infection was
correlated with induction of the liver-specific microRNA-122 and modulation of cellular factors that affect HCV replication.
RNA interference directed toward essential cellular cofactors in stem cells resulted in HCV-resistant hepatocyte-like cells
after differentiation. The ability to infect cultured cells directly with HCV patient serum, to study defined stages of viral
permissiveness, and to produce genetically modified cells with desired phenotypes all have broad significance for host-
pathogen interactions and cell therapy.
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Introduction
Chronic infections by hepatitis viruses such as hepatitis B virus
(HBV) and hepatitis C virus (HCV) afflict more than 550 million
people worldwide and cause serious liver diseases such as cirrhosis
and hepatocellular carcinoma (HCC) [1,2]. These end-stage
diseases destroy the self-regenerating ability of the organ and
commonly require liver transplantation for patient survival.
Unfortunately, in addition to the issue of donor shortage, HCV-
related liver-transplant patients, who account for almost half of
those on the waiting list, are confronted by the serious problem of
reinfection of the new graft. The current reinfection rate is 100%,
and disease progression appears to be accelerated with posttrans-
plant reinfection [3]. An alternative to solid organ liver transplant
is hepatocyte transplantation, which could help alleviate the
shortage of donor organs [4] and might allow blockade of
reinfection if the hepatocytes could be made resistant before
engraftment. Studies with immunodeficient mouse models indeed
demonstrated that purified primary human hepatocytes (PHHs)
could repopulate damaged mouse liver after transplantation [5–7].
Obtaining sufficient numbers of genetically modified PHHs has
not been possible, however, as these cells do not readily proliferate
ex vivo, so their expansion and genetic modification are restricted.
In addition, uninfected PHHs will necessarily be from a different
individual than the recipient, presenting the risk of transplant
rejection as in the case of solid liver transplantation.
PHH cultures, established from adult or fetal livers, also
represent the most physiologically relevant target cells for HCV
infection in vitro. Despite the popularity and success of the cell-
culture system based on the hepatoma cell line Huh-7 and its
derivatives [8,9], several important aspects of viral infection and
host responses cannot be studied in these cell lines. For example,
the highly permissive Huh-7.5 cells are defective in RIG-I-
mediated interferon production [10] and therefore not suitable for
studies of innate immunity to HCV infection. Cell lines outside the
Huh-7 series that can support HCV infection have been also
reported [11–15], but in addition to having much lower infection
efficiencies, these cells are either derived from tumor tissues or
immortalized, making them incompatible with any research
intended to determine potential oncogenic effects of viral infection.
Notwithstanding the importance of PHHs, the usefulness of these
cells as a robust culture model for HCV research has been
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Procurement of liver biopsy and freshly isolated hepatocytes is
difficult for the majority of the researchers, and the commercial
supplies of PHHs can be unpredictable because of the low plating
efficiency of the cells. The variability of PHHs isolated from
different patients is another challenge. Differences in patient
medical history, host genetics, and methods of isolation all
contribute to the difficulty of obtaining reproducible results and
comparing data from different labs. For example, Podevin et al.
[16] noted that PHH cultures established from patients who had a
history of heavy alcohol use were not suitable for infection by
HCV produced in cell culture (HCVcc). Finally, in studies of
interferon (IFN) production in response to HCV infection where
experiments cannot be performed with Huh-7.5 cells, special care
has to be taken to eliminate the potential co-purification of
nonparenchymal cells from liver tissue as those can complicate
results regarding the cellular source for IFN production [17].
The source of infectious HCV particles that can be used in
infection studies in cell culture is also limited. The discovery of a
genotype 2a genome (JFH-1) that could replicate in cell culture
without adaptive mutations [18] led to the production of infectious
HCVcc particles [19–22], now ubiquitously used in cell-culture
experiments. These JFH-1–based viruses, along with additional
chimeras [23,24] and a genotype 1a virus that could also produce
particles when adaptive mutations were introduced into its
genome [25], greatly advanced the cell culture model beyond
the subgenomic replicon stage and allowed studies of the full life
cycle of HCV. Nevertheless, HCV particles derived from patient
serum (HCVser) may differ from HCVcc in important aspects
such as buoyant density and virion-associated serum products that
are only present in vivo. HCVser infection in vitro has been
inefficient, and a recent study with the human liver progenitor cell
line HepaRG suggests that both immature and mature hepatocyte
features are required for efficient infection and replication of
HCVser [12].
Emerging stem cell technologies may offer an elegant solution to
these problems. Pluripotent stem cells, either embryonic or
induced by reprogramming factors (hESCs and iPSCs, respec-
tively), have the remarkable ability of indefinite self-renewal while
maintaining their potential to differentiate into virtually any cell
type [26,27], including hepatocyte-like cells [28–35]. In vitro
differentiated human hepatocyte-like cells (DHHs) express hepatic
markers and display hepatic function. More importantly, DHHs
were able to repopulate mouse liver and exhibit hepatic function
after transplantation in a liver-damaged mouse model [36].
Combining genetic manipulation of pluripotent cells with directed
hepatic differentiation holds great promise for generating virus-
resistant hepatocytes to be used in a potential life-saving therapy,
but whether DHHs can be productively infected by HCV has not
been studied, so their utility in the setting of HCV-related
hepatocyte transplantation has not been explored. Here we report
a proof-of-concept study designed to investigate the permissiveness
of DHHs to HCV infection as well as the feasibility of genetically
modifying pluripotent stem cells and the resulting DHHs to render
them resistant to HCV infection. We demonstrated that DHHs
derived from both hESCs and iPSCs could be persistently infected
with both HCVcc and HCVser, and knocking down critical
cellular cofactors for HCV replication [37] in the stem cells before
hepatic differentiation generated hepatocytes that were refractory
to HCV infection. We also discovered a critical transition stage at
which the differentiated cells became susceptible to HCV
infection, revealing a mechanism of HCV’s tropism for hepato-
cytes; and potentially exposing additional vulnerabilities of the
virus.
Results
In vitro differentiated hepatocytes derived from either
hESCs or iPSCs are permissive to HCV infection
We first determined whether DHHs derived from directed
differentiation of hESCs or iPSCs were susceptible to infection by
HCVcc. A serum-free protocol based on chemically defined
culture media [32,38] was used to differentiate the hESC line
WA09 (H9) [26] or the iPSC line (iPS.K3) [31] into hepatic
lineage cells that expressed various hepatic markers at different
stages of differentiation (Figure 1A; Figure S1 in Text S1). The
expression of a pluripotency marker, Oct 4, was high in stem cells
but decreased in the definitive endoderm (day 4), whereas the
endoderm marker CXCR4 exhibited the reciprocal expression
pattern (Figure 1A, panels a–f). The mRNA level of another
pluripotency marker, Nanog, also decreased at day 4 and became
undetectable at later days (Figure 1B). At day 10 after
differentiation, the cells were positive for either alpha-fetoprotein
(AFP) or cytokeratin-7 (CK-7) but not both, a pattern suggesting
that they are of a composition similar to that of the bipotent
hepatoblasts (Figure 1A, panel h); AFP expression steadily
increased in the next five days from 5% at day 10 to over 90%
at days 13–16. The intensity of AFP staining then decreased when
albumin (ALB) started to be expressed in approximately half of the
cells towards the end of the differentiation protocol (Figure 1A,
panels j–o). Quantitative reverse-transcriptase coupled PCR (qRT-
PCR) confirmed that the ALB mRNA continuously increased
during differentiation, as did the alpha-1 antitrypsin (AAT) mRNA
(Figure 1C). Secretion of ALB into culture medium was evident
from day 12 after differentiation and highest after 18 days
(Figure 1D). Finally, Periodic acid-Schiff staining revealed that
over 80% of the cells at day 18 were capable of glycogen storage
(Figure 1E).
We used three distinct variants of JFH-1 for the initial infection
at day 13 and then collected cell lysates at the end of the
differentiation period (day 21) for western blotting to detect HCV
protein expression. The multiplicity of infection (m.o.i.) used was
Author Summary
Physiologically relevant cell-culture models for infection
with hepatitis C virus (HCV) are scarce, and infection by
viruses derived from patient serum has been inefficient.
Differentiated human hepatocyte-like cells derived from
pluripotent stem cells demonstrate hepatic functions but
have not been explored for HCV infection studies. Here we
report a novel infection model based on these hepatocyte-
like cells. Stem cells and definitive endoderm successfully
resisted HCV infection, whereas hepatic progenitor cells
derived from the stem cells were productively infected by
both human- and cell-culture-derived HCV. We determined
the point of transition from resistance to susceptibility and,
by comparative gene profiling, identified the host factors
that were correlated with susceptibility. Genetic modifica-
tion of human embryonic stem cells, coupled with hepatic
differentiation, generated hepatocyte-like cells that were
resistant to HCV infection. Our study establishes a new
noncancerous and renewable cell-culture system for HCV
infection, permits direct infection of cells by patient sera in
vitro, identifies a defined transition to HCV susceptibility
during hepatocyte differentiation, and demonstrates the
feasibility of generating virus-resistant human hepatocyte-
like cells in vitro.
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increased their infectious titers by at least 100-fold over the JFH-1
wildtype (wt) background. Mut4-6 has been reported previously
[39] and the serially adapted virus (SAV) was obtained by repeated
passage of JFH-1 HCVcc in Huh-7.5 cells. The third HCVcc
variant is Jc1/GLuc2A, a J6/JFH chimera with a Gaussia luciferase
(GLuc) reporter gene incorporated [40]. Expression of HCV
proteins, core, NS3, and NS5A were readily detected by western
blotting for all three HCVcc preparations (Figure 2A). Intracel-
lular expression of HCV antigen was also detectable by
Figure 1. Hepatic differentiation from human embryonic stems cells (hESCs). (A) Representative images of cell morphology and protein
marker expression of hESCs (day 0), definitive endoderm (day 4), hepatic progenitor cells (days 8–10), and hepatocyte-like cells (both immature and
mature, days 11–21). For day-10 cells, double-staining of AFP and CK-7 (middle panel, 406) showed mutually exclusive expression in the cell
population. (B) Reciprocal expression of pluripotent marker Nanog and liver-specific marker AFP during differentiation. RT: reverse transcriptase. (C)
Expression of mRNAs of ALB and AAT during differentiation. PHH: primary human hepatocytes; (D) Albumin secretion by differentiated human
hepatocyte-like cells (DHHs). Culture media were collected at the indicated time points during differentiation and subjected to albumin detection
with an ELISA kit. Error bars represent standard deviation from replicate experiments. (E) Periodic acid-Schiff staining of stem cells (WA09), DHHs, and
PHHs.
doi:10.1371/journal.ppat.1002617.g001
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variant that encoded a FLAG-tagged NS5A (Figure 2B). In
addition, we confirmed infection events in single cells by
introducing an HCV-dependent fluorescence relocalization
(HDFR) reporter construct [41] into the day-10 cells and
monitoring the nuclear translocation of a fluorescent protein
upon cleavage of its mitochondria anchor by the HCV NS3
protease (Figure 2C). To determine whether HCVcc infection of
DHHs depended on viral glycoproteins and cell-surface receptors,
we performed the infection in the presence of a neutralizing E2
antibody [42] and a small-molecule compound that inhibits the
scavenger receptor class B type I (SR-BI) binding [43]. Both agents
efficiently blocked infection, as did the replication inhibitor IFN-a
(Figure 2D). A comparison of HCV expression levels in similarly
infected DHHs (WA09-derived) and PHHs (isolated from a
patient) revealed that efficiency of infection in DHHs is
comparable to that in PHHs (Figure 2E). Finally, DHHs derived
from an iPSC cell line (iPS.K3) also supported robust infection by
all three derivatives of the JFH-1/HCVcc (Figure 2F).
DHHs support persistent infection and produce
infectious particles
To verify continuous viral replication during the infection
period, we monitored the secretion of Gaussia luciferase into the
culture medium by the DHHs infected with the GLuc reporter
virus, using a procedure previously used to monitor persistent
HCV infection in microscale PHHs [44]. After the initial infection,
the viral inoculum was removed and replaced with fresh medium,
a fraction of which was then collected immediately (0 h), one day
(24 h), and two days (48 h) after the virus removal. At the 48-h
time point, the cells were washed again and changed into fresh
media which was then collected in a similar fashion. This process
was repeated until day 21, when the DHHs became senescent and
died off the plates. A gradual increase of the luciferase activity was
detected in the culture medium after each removal, whereas the
signal increase was not observed in medium from either mock
infected cells or from infected cells treated with cyclosporine A
(CsA), an inhibitor of cyclophilins and HCV replication [45]
(Figure 3A). In addition to persistent replication, production of
infectious viral particles was also achieved in DHHs infected with
HCVcc. WA09-derived DHHs were infected at day 11 after
differentiation, and culture supernatants were collected 48 h after
infection. HCV core antigen was detected in the supernatant of
the infected cells but not in that of the similarly infected but IFN-
treated cells (Figure 3B). To determine whether the core-positive
culture supernatant contained infectious viral particles, we used
these supernatants to infect Huh-7.5 cells. NS3-positive foci could
be clearly detected in the infected cells (Figure 3C), demonstrating
that DHHs were capable of supporting infectious particle
production.
Transition from non-permissive to permissive cells
We next determined the transition stage during differentiation
that rendered the DHHs susceptible to HCV infection. The
hepatic differentiation protocol that we used involved five different
medium compositions for the various stages of differentiation
(Figure 4A). A combination of Activin A, basic fibroblast growth
factor (b-FGF), and Wnt-3A (Media A and B) was used to induce
the differentiation of definitive endoderm (days 1–4), which was
cultured in a FGF-10-containing medium (medium C) for three
days (days 5–7) for initiation of definitive endoderm hepatic
specification. After day 7, medium C was supplemented with
retinoic acid (RA) and a transforming growth-factor-b (TGF-b)
inhibitor, SB431542, and the cells were cultured for three
additional days (days 8–10) in this medium (medium D). Finally,
the hepatocyte-like cells were allowed to mature in medium E,
which contained hepatocyte growth factor (HGF), epidermal
growth factor (EGF), and FGF-4 (days 11–21). We exposed cells at
different time points to GLuc-based HCVcc for 6 h, removed the
inoculum, and then monitored infection by measuring both
intracellular NS3 expression and luciferase activity in the medium
48 h after infection. A clear infection signal was detected in cells at
and after day 10 after differentiation, whereas the stem cells (H9),
the definitive endoderm, and cells up to day 9 after differentiation
could not be infected (Figure 4B and 4C). Because the day-10 cells
were normally changed into medium E immediately after the
removal of the viral input, we wanted to determine whether
medium E was required for the infection. To address this question,
we performed an experiment in which the infected day-10 cells
were either kept in medium D (FGF-10, RA, and SB) or changed
into medium E (HGF, EGF, and FGF-4). Both samples were
collected at day 21 and subjected to immunoblotting for detection
of HCV proteins. medium E was not required for HCV
permissiveness, as both cell populations became infected, but the
maturation process may further increase the infection efficiency
(Figure 4D, compare lanes 2 and 3). These results identify a
discrete temporal switch during the hepatic differentiation process
that marks the transition to permissiveness for HCV infection
(Figure 4E).
Cellular changes associated with HCV permissiveness
We then sought to identify the cellular determinants whose
induction or repression by the hepatic specification process was
correlated with permissiveness to infection. Liver-specific genes
that are important for HCV infection are good candidates for such
determinants. The microRNA miR-122 is such a cellular cofactor
[46–48]. Expression of miR-122 was not detectable by real-time
RT-PCR in day-0 or day-4 cells but was greatly induced at day 7
and then maintained throughout the differentiation process
(Figure 5A). These data suggested that the induction of miR-122
expression by hepatic specification conditions contributed to, but
Figure 2. Infection of DHHs derived from hESCs and induced pluripotent stem cells (iPSCs). (A) Detection of hepatitis C virus (HCV)
proteins in DHHs infected with JFH-1 based HCV derived in cell culture (HCVcc). DHHs were inoculated with three different preparations of HCVcc at
day 13 after differentiation, and cell lysates collected at day 21 for western-blot analysis. The anti-NS3 antibody also recognized a nonspecific band in
the mock-infected sample. (B) Immunostaining of infected DHHs. A JFH variant containing a FLAG tag in the NS5A protein was used to infect either
Huh-7.5 or DHHs, and staining was done with an anti-FLAG antibody. (C) Infection of Huh-7.5 and DHHs as measured by the HCV-dependent
fluorescence relocalization assay. Reporter-transduced cells were infected with HCVcc, and the cells were fixed for immunofluorescence analysis 72 h
after infection. For the RFP-NLS-IPS expressing cells, HCV infection led to complete nuclear translocation of the RFP; for the EGFP-IPS cells, HCV
infection led to redistribution of green fluorescence from a reticulate cytoplasmic pattern to a diffused pattern with nuclear enrichment. (D) HCV
inhibitors abolished infection in DHHs. The following inhibitors were included in the infection experiments. IFN: interferon-a, 80 units/ml; AR3A: anti-
E2 neutralizing antibody, 1 mg/ml; ITX: ITX5061, an SR-BI inhibitor, 1 mM. (E) Comparison of HCVcc infection levels in DHHs and primary human
hepatocytes. Primary human hepatocytes were infected for 8 days, for comparability with the DHHs, which were infected at day 13 and the lysed at
day 21. (F) Infection of DHHs derived from an iPSC line. Differentiation and infection of iPS.K3 were performed as described for H9-derived DHHs
(Figures 1 and 2A).
doi:10.1371/journal.ppat.1002617.g002
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permissiveness. We next performed microarray analysis to
compare gene-expression profiles of day-7 (non-permissive) and
day-10 (permissive) cells. The addition of medium D resulted in
changes in expression levels of hundreds of genes, many of which
are associated with cell signaling pathways or function of
extracellular components (Dataset S1). We focused on genes that
have been previously implicated in HCV infection. Expression of
the four well-characterized receptors (cluster of differentiation 81
(CD81), SR-BI, claudin-1, and occludin) remained largely
unchanged, as did the expression of the putative attachment
factor, the low-density lipoprotein receptor (LDL-R, Figure 5B).
The expression of epidermal growth factor receptor (EGFR) and
ephrin receptor A2 (EphA2), two receptor tyrosine kinases (RTKs)
identified in an siRNA library screening for HCV entry factors
[49], increased in day-10 cells (Figure 5B). Quantitative RT-PCR
confirmed the upregulation of these genes (Figure 5C) to be
comparable with the levels found in PHHs (Figure S2A in Text
S1). In addition, phosphatidylinositol 4-kinase type III alpha
(PI4KIIIa), another critical HCV cofactor [50–52], was also
induced in day-10 cells, especially at the protein level (Figure 5D).
In contrast, the expression of most other reported cellular
cofactors of HCV remained unchanged (Figure S2 in Text S1).
Immunostaining of cell surface receptors confirmed the RNA data
from microarray and conventional RT-PCR (Figure S3 in Text
S1). Finally, there were also many genes that were down-regulated
in day-10 cells compared to day-7 cells. One of these encoded the
interferon-induced transmembrane protein 1 (IFITM1)
Figure 3. Persistent and productive infection of DHHs by HCVcc. (A) Continuous replication of HCVcc in DHHs. Day-10 DHHs were exposed to
Jc1/GLuc2A for 9 h before the inoculum was removed and the cells were changed to medium E with or without cyclophilin inhibitor CsA at 1 mg/ml.
Culture supernatants were collected daily for measurement of luciferase activity. The culture medium was replaced with thorough washing every
48 h, and CsA was included every time fresh medium was used. Error bars represent standard deviations from triplicate experiments. (B) Secretion of
HCV core antigen into the culture medium by infected DHHs. Day-13 DHHs were exposed to HCVcc for 9 h before the inoculum was removed, and
the cells washed and changed to medium E, then immediately collected as the 0-h samples. The infected cells were then incubated for an additional
48 h in medium E with or without IFN-a (50 units/ml) before the culture supernatants were collected as the 48-h samples. Error bars represent
standard deviations from replicate experiments. (C) Reinfection of Huh-7.5 cells by HCV particles produced from DHHs. The 48-h media from (B) were
used to infect Huh-7.5 cells, which were then fixed for NS3 staining four days after infection. The infectious titer of the HCVcc produced by DHHs is
shown. FFU: focus-forming units.
doi:10.1371/journal.ppat.1002617.g003
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repress HCV replication and down-regulation of which by siRNA
increased HCVcc infection in Huh-7.5 cells [53]. Taken together,
these results suggest that transition to HCV permissiveness during
the in vitro differentiation process may require both the activation
of positive factors (miR122, EGFR/EphA2, PI4KIIIa etc.) and the
downregulation of antiviral genes such as IFITM1.
Genetic modification to generate HCV-resistant DHHs
A distinct advantage of DHHs over PHHs is the potential to
modify the cells genetically at the pluripotent stage and then
produce DHHs with the desired phenotype. We introduced a
small-hairpin RNA (shRNA) directed at cyclophilin A (CyPA) into
WA09 cells by lentiviral vector-mediated gene delivery. This
shRNA, sh-A161, had previously been shown to block HCV
infection in a human hepatoma cell line Huh-7.5 by knocking
down expression of CyPA [37]. The importance of CyPA in the
HCV life cycle has been validated clinically with cyclophilin
inhibitors in patient trials [54]. Suppression of CyPA expression in
WA09 cells was similarly achieved by stable expression of sh-A161
(Figure 6A), and the resulting KD cell line (WA09-LA) retained
normal expression of the pluripotent marker Oct-4 (Figure 6B).
When WA09-LA cells were subjected to the hepatic differentiation
procedure to produce DHH-LA, the knockdown of CyPA was
maintained in the differentiated cells (Figure 6A), indicating long-
term suppression of gene expression by shRNA was not affected by
the differentiation steps as long as a house-keeping promoter was
selected to drive the shRNA expression (e.g. a murine U6
promoter contained in the lentiviral construct used in this study).
Infection by wildtype HCVcc, however, was reduced to the mock
level in DHH-LA cells (Figure 6C, red dotted lines) cells.
Importantly, these cells remained permissive to infection by a
CyPA-independent mutant virus (GLuc-DEYN) (Figure 6C, blue
lines), recently isolated by means of a genetic approach termed
cofactor-independent mutant (CoFIM) selection [55]. These data
suggest that the block to HCV infection was due to CyPA
knockdown rather than to a non-specific effect of the shRNA
expression [56]. A second WA09 line harboring an shRNA
Figure 4. Time course of infection for determination of the transition point at which the differentiating cells became permissive for
HCV. (A) List of growth factors in media used in the various stages of differentiation. (B) Time course of DHH infection. Cells were exposed for 6 h on
the indicated days before the inoculum was removed. The cells were then cultured in the appropriate medium for an additional 48 h before the cell
lysates were collected for detection of NS3 expression. (C) Secreted luciferase activities were monitored in the same experiments described in (B).
Error bars represent standard deviation of triplicate experiments. (D) Hepatic maturation was not required for HCV infection of day-10 cells. Day-10
DHHs were infected and then either kept in medium D (hepatic specification medium) or changed to HGF-containing Medium E (hepatic maturation
medium) until day 21, when all cells were collected for western blotting. The anti-NS3 antibody also recognized a nonspecific band in the mock-
infected sample. (E) A diagram indicating the time point for transition of DHHs to HCV permissiveness on the basis of results shown in (B) and (C).
doi:10.1371/journal.ppat.1002617.g004
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differentiation (Figure S4 in Text S1), lending further support to
the broad utility of the modification/differentiation technology.
Patient serum–derived HCV infects DHHs but not Huh-
7.5 cells
Although robust infection of PHHs by HCVcc has been
reported [16,44,57], direct infection by HCVser remained
inefficient [16,58]. We infected DHHs with HCVser of two
genotypes: a genotype-1b patient serum that contained high-titer
HCV RNA copy numbers (1.8610
6 copies/ml) and a genotype-1a
patient serum that had been previously demonstrated to be
infectious in the Alb-uPA mouse model [5] (RNA titer of 1610
6
copies/ml). The DHHs were infected at the indicated multiplicity
of infection for 48 h before the cells were lysed for analysis of
HCV protein expression. Infection was readily detectable by
western blotting and sensitive to IFN inhibition (Figure 7A),
although the infection signal of HCVser was weaker than that of
the HCVcc. HCVser infection was also detectable with the HDFR
assay (Figure 7B). In addition, secretion of HCV core antigen was
detected in the supernatant of the DHHs infected by HCVser
(Figure 7C). In contrast, exposure of Huh-7.5 cells to HCVser of a
Figure 5. Cellular determinants of HCV susceptibility. (A) Induction of microRNA miR-122 expression by FGF-10 during hepatic specification.
Equal amounts of total cellular RNA from various cells at the indicated days were subjected to a real-time RT-PCR assay for detection of miR-122
expression. (B) Microarray heat map of gene expression levels in day-10 versus day-7 cells. Two independent RNA samples were processed for each
time point. The numbers represent the average values and standard deviations. The conventional color spectrum with green representing
downregulation and red representing upregulation was adopted. Fold of changes were also listed next to the name of the gene. (C) Quantitative RT-
PCR results of EGFR and EphA2 induction. (D) Upregulation of PI4KIIIa protein during the differentiation process. The levels of CyPA and DDX-3
remained unchanged in the same samples. (E) Quantitative RT-PCR results of IFITM1 and IFI30 expression induction.
doi:10.1371/journal.ppat.1002617.g005
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intracellular expression of NS3 (data not shown) or any release of
HCV core into the culture medium (Figure 7D). Genome
sequencing did not reveal any adaptive mutations that have been
reported in the literature (data not shown). Given the high
permissiveness of Huh-7.5 cells to HCVcc infection, these results
strongly suggest that HCVser preferentially infects the non-
cancerous DHHs.
Discussion
We have demonstrated that hepatic cells derived by directed
differentiation of stem cells, including iPSCs, can support HCV
infection. Complete life cycles of HCV infection could be
completed starting with HCV entry and ending with secretion of
infectious viral particles into culture media. Infection of DHHs
was sensitive to replication inhibitors as well as entry blockers.
Four different variants of JFH-1, including a J6/JFH hybrid
(GLuc), were used to produce HCVcc used in this study. Both
wild-type sequence (JFH-FLAG) and adaptive mutants (SAV and
Mut4-6) were able to replicate in DHHs, indicating that the ability
for DHHs to support HCV infection did not depend on particular
isoforms or mutations. In addition, successful infection by two
clinical isolates of genotype 1a and 1b demonstrated the feasibility
of using DHHs to study these genotypes that are prevalent in
patients but understudied in cell culture [25,59]. Beyond the
genotype considerations, direct infection by patient serum also has
broad significance for challenging research areas such as the
dissection of drug resistance mechanisms and functional charac-
terization of authentic HCV particles. Silberstein et al. [60]
recently demonstrated the long-term passage of a genotype 1b
clinical isolate in a monkey kidney cell line (VeroE6) that was
defective in type I IFN production. High titer of infectious viruses
could be recovered and this isolate was able to recapitulate the in
vivo IFN resistant phenotype in cell culture. This virus, however,
was highly cytotoxic to Huh-7.5 cells, somewhat limiting the study
of persistent infection in human hepatic cells. Interestingly,
although the 1a serum used in this study was obtained from a
patient who was discontinued from pegylated IFN/Ribavirin with
significant side effects and poor response to treatment, infection by
this virus was sensitive to IFN treatment in vitro. Host
determinants may have been responsible for the IFN resistance
observed in vivo for this patient.
The DHHs represent an important addition to the small field of
in vitro models for HCV infection. In contrast to the cell lines
derived from tumor tissues, DHHs are non-cancerous and retain
important functions of primary hepatocytes such as secretion of
ALB, glycogen storage, LDL uptake, cytochrome P450 function,
and the ability to replace mouse hepatocytes in liver injury mouse
models. DHHs also offer advantages over PHHs as being more
Figure 6. Genetic modification of hESCs and HCV-resistant DHHs. (A) Suppression of CyPA expression by shRNA in WA09 cells and day-21
DHHs. (B) CyPA knockdown did not affect the expression of pluripotency marker Oct-4 in WA09 cells. (C) Modified DHHs were resistant to wildtype
HCV infection. Infection of both the wildtype and CyPA-KD (LA) DHHs were done at day 13 and allowed to proceed for 48 h. Luciferase in the culture
supernatant for monitored. Wildtype HCVcc (Jc1/GLuc2A) infected unmodified DHHs but not CyPA-KD DHHs (redlines), and the DEYN mutant
infected both cell types (blue lines). Error bars represent standard deviations of replicate experiments.
doi:10.1371/journal.ppat.1002617.g006
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groups recently reported the direct induction of mouse fibroblasts
into hepatocyte-like cells (iHep) [61,62]. Whether a similar feat
can be accomplished for human cells and, if so, whether the iHep
cells will have enough proliferative potential to serve as a useful
model for HCV research remain to be determined.
Genetic modification of pluripotent stem cells before directed
differentiation is an attractive approach to obtaining specific cell
types with desired phenotypes. In the context of HCV infection
and liver disease, stem-cell lines with essential cellular cofactors
knocked out or knocked down can serve as a renewable source of
HCV-resistant hepatocyte-like cells in vitro, which can in turn be
used in transplant experiments. Even though most cellular proteins
probably play essential roles normally, and their silencing cannot
be reasonably expected not to affect the host, the opportunity for
inhibiting a cellular cofactor does sometimes arise as a result of
functional redundancy at the cellular but not the viral level, as is
the case with the HIV coreceptor C-C chemokine receptor type 5
(CCR5) [63]. For RNA viruses with high mutation and turnover
rates, inhibiting a cellular rather than a viral target may offer the
advantage of a higher genetic barrier to development of resistance.
Gene knockout technology in mouse embryonic stem cells
revolutionized the field [64] and remains the gold standard for
definitive studies of gene function, but the robustness of the
technology did not transfer to hESCs easily [65]. The efficiency of
homologous recombination in hESCs and human iPSCs is much
lower, in part because the pluripotent state of the human cells
resembles that of the mouse-derived epiblast stem cells, rather than
the true naı ¨ve state of the mouse embryonic stem cells [66,67].
Further reprogramming of human iPSCs with leukemia inhibitory
factor [67] or significantly increasing the size of the targeting
vector [68] may be required to produce an acceptable rate of
recombination. RNA interference, on the other hand, appears to
function efficiently in all cell types and represents an alternative to
gene knockout, especially when partial suppression of a cofactor is
sufficient to reduce viral infection in a meaningful way. This study
demonstrated that lentiviral vector–mediated expression of
shRNA can be maintained in long-term differentiation cultures
and that CyPA KD in hESCs or DHHs has no apparent adverse
effects on pluripotency or differentiation. The CyPA KD DHHs
were permissive to infection by an HCV mutant with reduced
dependence, further indicating that these modified cells retained
Figure 7. Direct infection of DHHs by HCV derived from patient serum. (A) Detection by western blotting of IFN-sensitive infection by HCV
particles derived from patient serum (HCVser). IFN-a was included in the medium at 50 units/ml when indicated. The multiplicity of infection for the
individual viruses was: HCVcc: 0.5; Serum 1a: 0.02; Serum 1b: 0.5. (B) Visualization of single-cell infection events by HCVser with the HCV-dependent
fluorescence relocalization assay. Arrows indicate individual cells infected with genotype 1b HCVser and showing nuclear translocation of the RFP.( C)
Secretion of HCV core antigen into culture supernatant by HCVser-infected DHHs. Values for core levels in supernatants collected 48 h after infection
were plotted. IFN-a was included in the medium at 50 units/ml when indicated. Error bars represent standard deviation of replicate experiments. (D)
HCVser preferentially infected DHHs over Huh-7.5 cells. Equal amounts of genome equivalent of HCVser were used to infect either Huh-7.5 or day-11
DHHs. Core levels in the supernatants collected at 0 and 48 h were plotted for both cell lines. Error bars represent standard deviations of replicate
experiments.
doi:10.1371/journal.ppat.1002617.g007
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are also consistent with the finding that CyPA-null mice developed
normally and had life expectancy comparable to that of wildtype
mice [69].
The efficiency of PHHs to support HCV production is typically
much lower than that of Huh-7.5 cells and varies in different
studies [16,44,57], presumably because of the different batches of
PHHs used or cell culture conditions or both. A similar situation
was observed with DHHs: despite robust intracellular expression
of HCV proteins and unequivocal evidence of virion production in
the culture medium of the infected DHHs, the infectious titers
have so far remained relatively low. This could be due to
interferon produced in the medium or may reflect the inherently
low infection efficiency in primary cells [17,70]. In addition,
expression of liver-specific marker genes such as ALB is much
lower in DHHs than in PHHs, suggesting the differentiation
protocol could be further optimized. Our preliminary experiments
showed that DHHs cultured in three-dimensional cell-culture
scaffolds conferred higher infectivity to HCVcc (Figure S5 in Text
S1), pointing to the possibility of improving DHH infection
efficiency by means of tissue engineering, as has been reported for
PHHs [44]. Interestingly, the relative efficiencies with which Huh-
7.5 and DHHs support HCVcc and HCVser infections were
distinctly different. HCVcc infected DHHs less efficiently than
they did Huh-7.5 cells, whereas HCVser specifically infected
DHHs but not Huh-7.5, suggesting that DHHs represent a more
physiologically relevant model for infection by clinical isolates of
HCV. Similarly, a GT1a infectious clone that failed to replicate in
Huh-7.5 cells was able to replicate and produce low numbers of
viral particles in PHHs cocultured with hepatic stellate cells [57].
The mechanism underlying this interesting phenomenon is
unclear at the present time, but may be related to, among other
possibilities, the different genotypes represented by HCVser and
HCVcc used in these studies. Both the Banaudha [57] study and
ours used HCVser of genotypes 1a and 1b whereas the HCVcc
were based on JFH-1 or J6/JFH, both of genotype 2a. It has been
documented that HCVcc based on genotype 1a is significantly less
infectious than the JFH-1-based HCVcc in Huh-7.5 cells [25].
Viral tropism for a specific cell type is typically associated with
the expression of tissue-specific cofactors (e.g. receptors). HCV
infection is largely hepatotropic although the virus has been
reported to infect other cell types, including B-cell lymphoma cells
[71]. Viral entry into DHHs by HIV and VSV particles
pseudotyped with HCV envelope proteins has been reported
[35,72], consistent with our finding that all known HCV receptors
are expressed on DHHs. We also found that the induction of miR-
122 expression was correlated with hepatic specification and
preceded the transition to HCV susceptibility, confirming the
connection between this liver-specific microRNA and host
restriction in non-hepatic cells, as first reported by Joplin et al
[47]. FGF-10 treatment, possibly in combination with the
withdrawal of Activin A, increased miR-122 expression by more
than several hundred fold. The link between FGF-10 and miR-122
induction may be the hepatocyte nuclear factor 4 alpha (HNF4a)
which, along with HNF6a, has recently been reported to bind the
miR-122 promoter and activate pri-miR-122 transcription
[73,74]. The expression HNF4a itself may be regulated by FGF-
10 as mutant zebrafish lacking the fgf-10 gene showed misexpres-
sion of HNF4a [75]. FGF-10 has also been shown to be crucial for
hepatoblast survival and proliferation [76], and an important role
of miR-122 in hepatic development has been demonstrated in
zebrafish [73], perhaps not surprising for a molecule that is highly
liver specific and extremely abundant (over 50,000 copies per cell
in mouse liver versus less than 50 copies in other tissues) [77]. It is
thus tempting to speculate that FGF-10 in part exerts its effect on
liver growth via the actions of miR-122. Besides miR-122, EGFR
and EphA2, two RTKs that contribute to the HCV entry process
through their kinase function, were specifically upregulated in
permissive cells. Of note, medium E, which contains EGF,
increased HCVcc infection of day-10 cells, consistent with
previously reported results in Huh-7.5 and PHHs [49]. The
expression of both ephrin A1, which is the ligand for EphA2, and
ephrin B2 also increased from day 7 to day 10. The latter is the
membrane-bound ligand for EphB and serves as a cellular
receptor for Nipah virus [78]. Whether it also plays any role in
the HCV entry process remains to be determined.
To our knowledge, ours is the first report of any cell type that
can be rendered permissive to HCV infection and replication by
treatment with defined chemical compounds. This important
advance opens up new possibilities for identifying novel signaling
pathways required for viral infection and could lead to the
discovery of new drug targets for HCV. Moreover, we have shown
that pluripotent stem cells can be genetically modified before
differentiation and then generate virus-resistant hepatocytes. In
addition to direct applications in studies of cellular cofactors in
infections or other diseases with a genetic component, the concept
illustrated here can be coupled with patient-specific iPSC
technology, especially if the potential immunogenicity issue [79]
can be overcome, to generate a multitude of cell types with desired
phenotypes for cell therapy.
Materials and Methods
Growth factors, chemicals and antibodies
Basic FGF (b-FGF), Stem Pro hESC SFM, b-mercaptoethanol,
and Geltrex were purchased from Invitrogen (Carlsbad, CA);
FGF-10, FGF-4, EGF, and HGF from PeproTech (Rocky Hill,
NJ); SB 431542 and retinoic acid from Sigma Aldrich (St Louis,
MO); Wnt-3A from Stemgent (San Diego, CA); Accutase from
Innovative Cell Technologies (San Diego, CA); Activin-A from
R&D systems (Minneapolis, MN); and Probumin from Millipore
(Billerica, MA). A list of antibodies used, along with providers and
catalog numbers, is given in Table S1 in supporting information
S3.
hESC, iPSC, and primary human hepatocytes
Human ESC line WA09 (H9) and iPS line iPS.K3 cells were
obtained from WiCell Research Institute and Stephen Duncan at
Medical College of Wisconsin, respectively. Stem cells were
maintained on Geltrex coated culture plates in Stem Pro medium
(Invitrogen, Carlsbad, CA). Freshly isolated PHHs were purchased
from Celsis In Vitro Technologies (Baltimore, MD) and
maintained according to provider’s instructions.
Differentiation of hESCs and iPS.K3 into hepatic cells
The base defined medium (DM) consisted of DMEM/F12
containing 10% Probumin, 0.2% b-Mercaptoethanol, 1% L-
Alanyl-L-Glutamine and 2% hESC supplement. Confluent cells
were harvested with Accutase and then plated into culture dishes
(Costar; Corning Life Sciences) precoated with Geltrex (1:200
dilution in DMEM/F-12) in Stem Pro medium at a confluence
level of 30–40%. The next day, culture medium was changed to
medium A (DM+100 ng/ml Activin-A+8 ng/ml b-FGF+25 ng/
ml Wnt-3A) for 24 hrs, followed by three days in medium B
(DM+100 ng/ml Activin-A+8 ng/ml b-FGF). To induce hepatic
differentiation, we then cultured cells in the presence of medium C
(DM+50 ng/ml FGF-10) for three days and then in the presence
of medium D (DM+50 ng/ml FGF-10+0.1 mMR A +1 mM
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cells were then split 1:2 and grown in medium E (DM+30 ng/ml
FGF-4+50 ng/ml EGF+50 ng/ml HGF) for 10 days with changes
to fresh medium E every two to three days.
Periodic acid-Schiff staining
The PAS staining was done on the stem cells, the day-18 DHHs,
and freshly isolated PHHs using a commercial kit (Sigma-Aldrich,
St. Louis, MO) per instructions provided by the manufacturer.
HCVcc and HCVser used in the infections
All JFH-1 based HCVcc (Mut4-6, SAV, Jc1/GLuc2A, and
DEYN-Jc1/GLuc2A) were produced in Huh-7.5 cells as previ-
ously described [20]. The genotype 1b HCV serum was obtained
from a commercial supplier (Teragenix, Ft. Lauderdale, FL), and
the 1a serum has been previously described [5]. All infections were
performed by incubation of virus inoculum with cells for 6–9 h
before the cells were washed and changed into the medium
appropriate for the specific cell type and differentiation stage. For
the time course of DHHs permissiveness, infection at each time
point was allowed to proceed for exactly 48 h before cell
harvesting and western blotting. Viral titers of HCVcc produced
from DHHs were performed with Huh-7.5-based cells and
measured in focus-forming units (FFU) per milliliter.
Immunofluorescence analysis of HCV receptors and
intracellular antigens
Cells were fixed in 4% paraformaldehyde in phosphate-buffered
saline (PBS) at room temperature for 10 min and blocked with
PBGB (PBS containing 10% normal goat serum, and 1% bovine
serum albumin (BSA)) at room temperature for 2 h. Cells were
incubated with primary antibodies (anti-CD81, anti-SR-B1, anti-
claudin 1 and anti-occludin, diluted in PBG at 1:200) at 4uC
overnight or 2 hrs at room temperature. Isotype mouse or rabbit
IgGs were used as negative controls. After four washes with PBSB
(PBS with 0.1% BSA), FITC or TRITC-conjugated secondary
antibody diluted at 1:500 was added and incubated at room
temperature for 1 hr. Before being mounted with VECTA-
SHIELD (H-1200, Vector Labs), cells were washed with PBSB
three times and once with PBTG (PBS containing 0.1% Triton X-
100, 10% normal goat serum, and 1% BSA). For intracellular
staining, we permeabilized the cells in PBST after fixing to allow
access by primary antibody.
HCV-dependent fluorescence relocalization assay
Lentiviral vectors expressing EGFP-IPS (TRIP-EGFP) or RFP-
NLS-IPS (TRIP-NLS-RFP) were provided by Charles Rice and
produced in 293-FT cells as previously described [41]. Day-10
DHHs or Huh-7.5 cells, seeded on coverslips the day before, were
transduced with the vectors for 24 h before being exposed to
HCVcc or HCVser for 6 h. The cells were cultured for 2–3 more
days before the slides were fixed for fluorescence microscopy
analysis.
Microarray and RT-PCR analysis
Complimentary DNA used for microarray hybridization was
prepared as follows. Total RNAs from day-7 and day-10 cells were
isolated with the Qiagen RNeasy Mini kit, and RNA was
converted into single-stranded cDNA with the High Capacity
cDNA Reverse Transcription kit (Applied Biosystems). The RNA/
cDNA hybrids were denatured at 95uC for 1 min and then treated
with RNase A for 30 min at 37uC. The resulting cDNA was
cleaned up with the Qiagen PCR purification kit before being used
for fluorescent labeling. A Nimblegen 4672K Expression Array
was used for hybridization according to the manufacturer’s
instructions. Expression data and gene ontology analysis were
done with ArrayStar (DNASTAR) and Gorilla (Technion -
Laboratory of Computational Biology). For RT-PCR, total RNA
was isolated from various days post-differentiation using TRIzol
and then converted to first-strand cDNA with SuperScript III
(Invitrogen) with oligo-dT serving as the RT primer. The resulting
products served as templates for PCR analysis of HCV cofactors
and receptors. Primer sequences for the hepatic markers and HCV
cellular cofactors are available upon request.
Real-time RT-PCR detection of micro-RNA 122 (miR-122)
To determine miR-122 levels, we reverse transcribed TRIzol-
extracted RNA samples using the TaqMan MicroRNA Reverse
Transcription kit (Applied Biosystems), and the resulting cDNA
served as templates for real-time PCR analysis with the TaqMan
MicroRNA Assay for miR-122 (Applied Biosystems).
Albumin and HCV Core ELISA
Albumin ELISA was performed with a human Albumin ELISA
kit (Bethyl Laboratories, Montgomery, TX), and HCV core
ELISA with the HCV Antigen ELISA kit (Ortho-Clinical
Diagnostics, Japan), according to manufacturer’s instructions.
Lentivirus-mediated RNA interference
Lentiviral vectors containing a shRNA directed at human CyPA
has been described previously [37]. A shRNA directed at
PI4KIIIa was constructed in a similar fashion. The shRNA target
sequence of the PI4KIIIa mRNA is 59-AAG CTA AGC CTC
GGT TAC AGA-39. These vectors were introduced into stem cells
by the standard lentiviral transduction procedure [80], and stable
cells harboring shRNA were selected by culture of the cells in Stem
Pro medium supplemented with 600 ng/ml of puromycin.
Supporting Information
Dataset S1 Microarray data comparing gene expression
profiles of day-7 and day-10 cells. List of genes and their
changes (folds up- or down- regulated) from day-7 to day-10 are
shown for two independent microarray experiments.
(XLSX)
Text S1 Supplemental Figures 1–5. Figure S1. Expression
of mRNAs of hepatic markers during differentiation. Expression
levels were normalized to GAPDH and the those of PHH was set
to be 1. ASGR1: asialoglycoprotein receptor-1; CyP3A: cyto-
chrome P450, family 3, subfamily A; PHH: primary human
hepatocytes. Figure S2. Expression of mRNAs of HCV cofactors
during hepatic differentiation. (A) Expression of EGFR and EphA2
mRNA in DHHs and PHHs. (B) Microarray heat map of
expression levels of reported HCV cofactors in day-10 and day-
7 cells. (C) Expression profile of HCV cofactors as represented by
conventional RT-PCR and gel analysis. Figure S3. HCV
receptor molecules expressed in stem cells. (A) Cell-surface staining
of the four well-characterized receptors (CD81, SR-BI, Claudin-1,
and Occludin) for HCV entry in both H9 and day-10 cells. (B)
RT-PCR analysis of receptor expression during the hepatic
differentiation process. Figure S4. PI4KIII knockdown in DHHs
block HCV infection. (A) Suppression of PI4KIIIa by shRNA in
Huh-7.5 cells. (B) PI4KIIIa KD efficiently blocked HCV infection
in Huh-7.5 cells. (C) PI4KIIIa KD in H9 cells. (D) DHHs with
PI4KIIIa KD were resistant to HCV infection. The cells were
infected at day 13, and the luciferase activity was monitored for
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experiments. Figure S5. Increased infection efficiency of DHHs
cultured in three-dimensional scaffolds. For the 3-D cultures, day-
9 cells were seeded onto either polystyrene or polycaprolactone
scaffolds, which were transferred to a new dish after adherence of
the cells. Infections by Jc1/GLuc2A were performed at day 13,
and luciferase assays in the next two days. The luciferase results
were normalized to the cell numbers and then compared with
those of the regular (2-D) cultures, which were set to be 100%.
Error bars represent standard deviations of replicate experiments.
(PDF)
Table S1 Antibody list. Name and source of the antibodies
(suppliers and catalog numbers) used in this study are listed.
(DOC)
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